Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. CHYM
3. BRZE
4. USO
5. QCOM
6. DYN
7. PHVS
8. UNFI
9. PYXS
10. JMKE

Go back to Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
(NYSE: TAK) Delayed: 18.32 --0 (-0%)
Previous Close $18.32    52 Week High $0.55 
Open $18.32    52 Week Low $0.55 
Day High $18.32    P/E N/A 
Day Low $18.32    EPS $-0.20 
Volume 188